Volumina is a clinical stage medtech start-up, spin off of EPFL.
We are active in the field of tissue engineering and develops Adipearl, an injectable biomaterial for the reconstruction of volumes of soft tissues (fat, muscles, glandular tissues, supporting and connective tissues) that have been lost after tumor ablation, disease, trauma, or for purely aesthetically purposes.
It addresses the need of patients wanting to regain durably their physical and functional integrity, as well as the need of plastic and reconstructive surgeons missing a safe and efficient solution to repair the body in 3D.

Preclinical and clinical studies performed to date have shown exceptional performance of Adipearl.

News

25.03.2024 Volumina Medical secures USD 21 million (startupticker.ch)
13.02.2024 Third LeadiNNg to Scale-Up Cohort unveiled (startupticker.ch)
04.10.2022 Volumina Medical wins notable new investors (startupticker.ch)
23.09.2021 Volumina Medical wins Prix Strategis 2021 (startupticker.ch)
17.06.2021 W. A. de Vigier prize for six startups (startupticker.ch)
12.05.2021 Finalists of the W. A de Vigier revealed (startupticker.ch)
06.04.2021 Prix Strategis 2021 Top 5 revealed (startupticker.ch)
30.11.2020 Prix Strategis 2021 Semi-finalists revealed (startupticker.ch)
10.07.2020 European funds for Swiss start-ups (startupticker.ch)

Milestones/News

08.05.2023 Swiss Accelerator Grant obtained
01.05.2023 Clinical results obtained
08.08.2022 Preclinical program completed
01.08.2018 Seed round

Vidéos et présentations


SCSN 2019

Player is loading...